Free Newsletter
FDA panel: Painkiller plan not strong enough
Free newsletter via e-mail
Tools
FDA advisory panel members overwhelmingly rejected a plan to reduce the misuse and abuse of long-acting painkillers like OxyContin, saying they did not think it was strong enough to control the use of such prescription narcotics. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: